Carbon hemoperfusion shows promise in canine meloxicam toxicosis
Bottom line
Carbon hemoperfusion sharply lowered serum meloxicam concentrations in five dogs treated for meloxicam toxicosis at three teaching hospitals, according to a new American Journal of Veterinary Research report. The retrospective case series covered dogs treated between January 2023 and March 2026 and found that synthetically derived activated carbon hemoperfusion reduced circulating drug concentrations substantially, building on an earlier 2025 case report that described an 87.5% drop in serum meloxicam after in-series hemoperfusion and hemodialysis in a single dog. The new paper suggests some centers are moving from one-off rescue use toward a more defined extracorporeal option for severe NSAID overdose. (doi.org)
Why it matters: For veterinarians, the study adds early clinical evidence that carbon hemoperfusion may meaningfully accelerate meloxicam clearance in dogs before gastrointestinal injury or acute kidney injury fully develops. That’s relevant because meloxicam and other NSAID exposures remain a common toxicosis problem in dogs, and traditional management has relied on decontamination, IV fluids, gastroprotectants, and monitoring, with extracorporeal therapies reserved for select referral cases. Recent IRIS best-practice guidance has also reinforced hemoperfusion’s role in toxin management when a significant toxin burden is likely to persist and the patient can safely undergo catheterization and treatment. (petpoisonhelpline.com)
What to watch: The next step is whether larger multicenter datasets can show not just lower serum drug levels, but better renal and gastrointestinal outcomes, clearer case-selection criteria, and practical referral thresholds for general practice. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Study type
- Retrospective case series
- Journal
- American Journal of Veterinary Research
- Sample size
- Five dogs
- Sites
- Three teaching hospitals
- Study period
- January 2023 through March 2026
- Exposure
- Meloxicam toxicosis
- Intervention
- Synthetically derived activated carbon hemoperfusion
- Main finding
- Serum meloxicam concentrations were markedly reduced
- Prior report
- A 2025 case report found an 87.5% serum meloxicam reduction over 207 minutes with hemoperfusion plus hemodialysis
A new American Journal of Veterinary Research study reports that carbon hemoperfusion markedly reduced serum meloxicam concentrations in dogs with meloxicam toxicosis, adding fresh evidence for extracorporeal treatment of severe NSAID overdose. The case series included five dogs treated at three teaching hospitals from January 2023 through March 2026, a small cohort, but one that points to growing clinical adoption of hemoperfusion in veterinary toxicology. (acmt.net)
The report builds on a short but quickly developing history. In 2017, clinicians described successful treatment of a meloxicam overdose in a dog using therapeutic plasma exchange, achieving an 82% reduction in plasma meloxicam concentration. In 2024, a separate case report described manual carbon hemoperfusion reducing meloxicam levels in a cat. Then, in 2025, a Journal of Veterinary Emergency and Critical Care case report documented what authors described as the first veterinary use of activated carbon hemoperfusion plus hemodialysis for canine meloxicam toxicosis, with an 87.5% reduction in serum meloxicam over 207 minutes. (pubmed.ncbi.nlm.nih.gov)
That progression matters because NSAID toxicosis is both common and potentially severe in dogs. Pet Poison Helpline lists meloxicam among drugs that can cause gastrointestinal ulceration, renal impairment, and neurologic signs when ingested at toxic doses. Broader outcome data in dogs with NSAID toxicosis show that standard treatment has typically centered on gastrointestinal decontamination, IV fluids, gastroprotectants, antiemetics, and, in some referral settings, lipid emulsion or plasma exchange. Hemoperfusion is now emerging as another option for patients with high-risk exposures, especially when the drug is highly protein-bound and still present in the circulation. (petpoisonhelpline.com)
The new AJVR paper appears to align with other recent signals that carbon hemoperfusion can remove NSAIDs efficiently. A 2025 abstract covering 18 dogs with NSAID toxicosis reported a median 91% reduction for meloxicam during carbon hemoperfusion, alongside marked shortening of drug half-life compared with published therapeutic half-lives in dogs. While conference abstracts are preliminary and not the same as peer-reviewed full papers, the consistency between that dataset, the 2025 single-case report, and this new five-dog series strengthens the case that the technique is pharmacokinetically effective. (pmc.ncbi.nlm.nih.gov)
Expert and industry commentary has also started to catch up. Tufts recently highlighted new guidance led by nephrology specialists on emerging blood purification options for veterinary toxicities, noting that toxic medication exposures are among the most common indications. Separately, the International Renal Interest Society’s hemoperfusion best-practices consensus states that newer adsorptive devices have expanded the role of hemoperfusion in veterinary medicine, while emphasizing careful patient selection, vascular access, and assessment of whether meaningful toxin burden remains. (vet.tufts.edu)
Why it matters: For veterinary professionals, this is less about proving hemoperfusion should replace standard care and more about identifying when referral medicine can change the trajectory of an overdose. If carbon hemoperfusion can rapidly lower meloxicam exposure early enough, it may reduce the risk or severity of downstream kidney and gastrointestinal injury in selected dogs. That could influence conversations with pet parents and referring veterinarians, particularly for large ingestions, delayed presentations, or patients already showing early laboratory changes. Still, access, cost, staffing, anticoagulation management, and extracorporeal expertise remain real barriers, so the practical value will depend on clearer treatment thresholds and outcome data, not serum concentrations alone. (animalemergencyaustralia.com.au)
What to watch: The field now needs larger peer-reviewed multicenter studies that connect drug removal with clinical endpoints, such as acute kidney injury rates, GI complications, length of hospitalization, and survival, while also clarifying whether standalone hemoperfusion is enough in most meloxicam cases or whether combination approaches with hemodialysis still have an edge in select patients. (doi.org)